digestive-diseases-2016_scientifictracks-abstracts

24 / 32

Volume 6, Issue 8(Suppl) J Gastrointest Dig Syst 2016
ISSN:2161-069X JGDS, an open access journal
Page 45
Notes:
Digestive Diseases 2016
December 08-09, 2016
conferenceseries.com
Digestive Diseases
December 08-09, 2016 Dubai, UAE
International Conference on
Management of chronic hepatitis C: A single center experience
Monir Hussein Bahgat, Shahira Aly El-Etreby and Salah El Gamal
Mansoura University, Egypt
Background & Aim: Treatment for HCV infection is undergoing a rapid evolution, offering new hope to both naïve and treatment-
experienced patients. Numerous highly effective, but expensive, direct acting antiviral (DAA) drugs active against different targets are
now available. The aim of this study is to investigate the efficacy and safety of DAAs with and without PEG-IFN-α 2a, and/or ribavirin
in treating chronic hepatitis C patients in Mansoura Specialized Medical Hospital.
Material & Methods: This observational study involved 181 patients with chronic hepatitis C presented to our Viral Hepatitis
Outpatient Clinic at Mansoura Specialized Medical Hospital for anti-viral therapy over an 18 months period from January 2015 to
June 2016. A total of sex different regimens were used depending on the national and international changing guidelines. All patients
were thoroughly assessed and followed up for SVR and side effects. Investigations involved Fibroscan & FIB-4 score for non-invasive
assessment of liver fibrosis, and serial HCV RNA assay by PCR.
Results: SVR12 for regimen 1 (PEG-IFN-α 2a + Sofosbuvir + Ribavirin) was 37/50 (74%), regimen 2 (Sofosbuvir + Ribavirin) was
40/56 (71%), regimen 3 (Sofosbuvir + Simeprevir) was 16/19 (78.9%), regimen 4 (Sofosbuvir + Daclatasvir ± Ribavirin) was 23/25
(92%), regimen 5 (Sofosbuvir + Ledipasvir) was 23/25 (92%), and regimen 6 (Paritprevir + Ombitasvir + Ritonavir) was 5/6 (83.3%).
Commonly reported side effects (>10%) included fatigue (66%), flu like symptoms (48%), dyspnea (40%), psychiatric changes (30%),
anemia (30%), cough (28%), nausea (24%), hypersensitivity (20%), rash (10%) for regimen 1. For regimen 2, fatigue (28.7%), cough
(26.8%), and anemia (26.8%). For regimen 3, fatigue (26.3%), hypersensitivity (26.3%), and rash (15.8%). For the other 3 regimens
fatigue was the only dominating side effect.
Biography
Monir Hussein Bahgat has done his specialization in Internal Medicine in the year 1995. Currently, he is a Professor of Hepatology and Gastroenterology (Internal Medicine
department), Manoura University Egypt. He is a member of EASL and IASL.
Monir Hussein Bahgat et al., J Gastrointest Dig Syst 2016, 6:8(Suppl)